Recent news

European Patent Office will grant a diagnostic CD73 patent for Faron
20120302.pdf (18.3 kt)

Faron has initiated development of GMP manufacturing of the humanized anti-Clever-1 antibody FP-1304 with Biovian

20111012.pdf (48.0 kt)

The FPCLI001 clinical trial with FP-1201 in acute lung injuries has been completed: also the long-term secondary end point demonstrates a significant decrease in mortality

20111007.pdf (39.6 kt)

Faron reports positive headline data from FPCLI001 clinical study with FP- 1201 in acute lung injuries

20110509.pdf (47.7 kt)
More news...

Faron is a virtual drug company focusing to discovery and development of proprietary new compounds/use for:

  • vasculopathies
  • traumas
  • inflammation
  • metastasis